Internationale Publikationen
Hier stellen wir eine Auswahl wissenschaftlicher Veröffentlichungen zur Verfügung, die im Zusammenhang mit der IOZK-Immuntherapie stehen.
Sie können mit Hilfe der Filter eine Auswahl nach Tumorarten und Methoden treffen, oder Suchbegriffe eingeben.
Potentiating prostate cancer immunotherapy with oncolytic viruses
Efficacy of intracellular immune checkpoint-silenced DC vaccine
Poly(I:C) enhanced anti-cervical cancer immunities induced by dendritic cells-derived exosomes
Myeloid and plasmacytoid dendritic cell vaccinations for castration-resistant prostate cancer patients.
Re-Emergence of Dendritic Cell Vaccines for Cancer Treatment
Pre-existing Immunity to Oncolytic Virus Potentiates Its Immunotherapeutic Efficacy
Radiation and Anti-Cancer Vaccines: A Winning Combination
Survival gain in glioblastoma patients treated with dendritic cell immunotherapy is associated with increased NK but not CD8 T cell activation in the presence of adjuvant temozolomide
Autologous tumor lysate-pulsed dendritic cell vaccination therapy after resection of stage IIA (T2N0, T3N0) esophageal cancer: An analysis of immunological responses.
A prospective, randomized, blinded, placebo-controlled, phase IIb trial of an autologous tumor lysate + yeast cell wall particles (YCWP) + dendritic cells (DC) vaccine vs unloaded YCWP + DC and embedded phase I/IIa trial with tumor lysate particle only (TLPO) vaccine in stage III and stage IV (resected) melanoma to prevent recurrence.
The effect of modulated electro-hyperthermia on temperature and blood flow in human cervical carcinoma
Hyperthermia enhances radiosensitivity of colorectal cancer cells through ROS inducing autophagic cell death
A phase-1/2 study of adenovirus-p53 transduced dendritic cell vaccine in combination with indoximod in metastatic solid tumors and invasive breast cancer
Newcastle disease virus co-expressing interleukin 7 and interleukin 15 modified tumor cells as a vaccine for cancer immunotherapy
EpCAM peptide-primed dendritic cell vaccination confers significant anti-tumor immunity in hepatocellular carcinoma cells
Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade
Buch Veröffentlichung von Prof. Dr. Schirrmacher: Quo vadis cancer therapy
Modulated electro-hyperthermia induced loco-regional and systemic tumor destruction in colorectal cancer allografts
Phase I clinical trial of a novel autologous modified-DC vaccine in patients with resected NSCLC
Antitumor Benefits of Antiviral Immunity: An Underappreciated Aspect of Oncolytic Virotherapies